Kura Oncology is a US-based biopharmaceutical company committed to treating cancer by developing small molecule products. The company’s portfolio focuses on developing medicines targeting genetically defined acute leukemias, solid tumors, and hematologic indications. Kura Oncology also has a clinical collaboration with Novartis to test the tipifarnib and alpelisib combination on patients with specific types of cancer.